A new biotech company pioneering therapies for patients with serious muscle diseases has launched this week with $50 million series A finding.
Dyne Therapeutics was founded, seeded and incubated and joined by Forbian and MP Capital in the financing round.
Dyne is developing breakthrough medicines based on its proprietary product platform, which delivers nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision.
The company’s lead programs are designed to knock down gene expression for the treatment of rare, monogenic neuromuscular diseases.
It is also developing therapeutics for patients with cardiac and smooth muscle diseases.
Dyne will initially focus on myotonic dystrophy type 1 (DM1), a rare, inherited disorder that causes muscle weakness and other life-limiting complications. There are currently no disease-modifying treatments for DM1, which affects an estimated 40,000 people in the US.
Dyne’s FORCE platform specifically targets muscle, minimizing systemic exposure. The company has completed preclinical studies indicating that this approach can deliver oligonucleotides that degrade disease-causing RNA, potentially restoring muscle health.
Dyne is led by a management team with extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities.
CEO Romesh Subramanian previously co-founded RaNA Therapeutics (now Translate Bio) and led new modality discovery research at Alexion Pharmaceuticals.